Algorae Pharmaceuticals (ASX:1AI) has appointed Troy Valentine as a Non-Executive Director to enhance its board’s expertise in capital markets and life sciences. Valentine, who previously led Incannex through significant growth, including a successful Phase 2 trial and U.S. FDA Fast Track designation, is expected to support Algorae’s strategy in commercial pharmaceutical supply and AI-driven drug discovery. His appointment follows the resignation of director Brad Dilkes and will be subject to shareholder approval at the next AGM. Executive Chairman David Hainsworth highlighted Valentine’s extensive experience as crucial for the company’s growth ambitions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://biotechdispatch.com.au/news/algorae-names-nasdaq-pharmaceutical-chairman-to-strengthen-board
